Sign up United Kingdom
Proactive Investors - Run By Investors For Investors
Market: AIM:SLN
52-week High/Low: 254.75p / 110.00p
Sector: Pharma & Biotech
Market Cap: 80.58M
Silence Therapeutics plc (LON:SLN)

Silence Therapeutics plc

We are a drug development company with a proprietary genetic medicine platform

Our technology harnesses the body’s natural mechanisms to create therapeutic effects within its own cells.  This technology can selectively silence or replace any gene in the genome, modulating gene expression up as well as down in a variety of organs and cell types, in vivo.

We have developed proprietary...

Silence Therapeutics plc

Interactive graph

col 3
col 4
col 5
col 6

Big picture - Why invest in Silence Therapeutics plc

Silence Therapeutics plc Snapshot

Our mission is to use our technology to create a new generation of therapeutics which can improve outcomes for patients and, in the process, build shareholder value.

Silence’s strategy is based on translating our intellectual property, our siRNA technology and delivery systems, into successful commercial drug products. We have the expertise and the patented technology required to develop siRNA based drug candidates internally as well as to establish fruitful collaborations with suitable partners.

Ensuring appropriate target gene selection and maintaining a diversified pre-clinical engine are key aspects of our strategic approach. We aim to evaluate as many potential applications of our technology as possible in the early, more affordable phases of our candidate-generating pipeline in order to better manage risk and the costs of failure.

Our strategy plays to the strengths of our platform technology, which include:

Our siRNA molecules are designed to target a single mRNA in the cell, only affecting the expression of the disease-causing gene. Our delivery systems ensure further specificity by delivering therapeutic siRNA only to one target cells in the body.

Modular technology
Our technology consists of two components: siRNA plus delivery system.

By engineering the siRNA molecule, a different gene can be targeted to tackle a new disease. This modular nature is the basis of our versatile platform technology.

Well understood mode of action
RNA interference is a well characterised natural pathway, which leads to the degradation of target mRNA. The precision of the RNA interference process translates in better predictability of the biological effects of siRNA based drugs.

Accelerated discovery timelines
Knowing the sequence of the human genome means that potent therapeutic siRNA molecules can be identified quickly, ready to be tested in the relevant models.



Our technology is a highly specific and modular platform that enables us to inhibit or ‘silence’ the expression of disease-causing genes, allowing cells to revert to their healthy state. We achieve this through harnessing the endogenous pathway of RNA interference (RNAi), which was a breakthrough discovery in the field of molecular biology that was first described in the late 1990s and later recognised with a Nobel prize in 2006.

Given the tailored inhibition of selected genes and the added precision brought by targeted delivery systems, RNAi-based therapies are thought to carry lower risk of failure than traditional approaches as the biological effects are more predictable. We are working to maximise the therapeutic applications of our versatile toolkit.


Click here for further information and here for details of the pipeline

* including indirect holdings and financial instrumentsNumber of securities in issue: 69,991,624 ordinary sharesPercentage of AIM securities not in public hands: 63.71% as at 30th September 2017.Last updated: 30th September 2017

Email - [email protected]

Corporate Headquarters - UK Germany
72 Hammersmith Road,
W14 8TH
t +44 (0)20 3457 6900

Nominated adviser and broker

Peel Hunt LLP
Moor House
120 London Wall

Legal adviser

Covington & Burling LLP
265 Strand


PricewaterhouseCoopers LLP
Abacus House
Castle Park


Capital IRG plc
Northern House
Woodsome Park
Fenay Bridge

Silence Therapeutics plc Timeline

July 17 2018
June 18 2018
April 24 2018
April 19 2018

Columns Including SLN


Market Reports Including SLN

Video RSS



© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use